Activation of Nrf2, which is equal to the inhibition of Keap1, can be a pharmacological target in certain diseases linked with oxidative stress and inflammation, such as cancer, as well as metabolic, vascular, and neurodegenerative diseases. The gene discussed is NFE2L2; the disease is neurodegenerative disease.